Spotlight On... A stunning Lilly warehouse heist puts security firm on trial; Merck has to face Bristol-Myers' PD-1 patent suit; Indian officials eye even bigger ban on combo meds; and more...

Six years after burglars pulled off daring heist at an Eli Lilly ($LLY) warehouse in Connecticut, a civil trial will explore whether the thieves got their hands on a report of the warehouse security weaknesses from ADT/Tyco. The suit, brought by one of Lilly's insurers, suggests someone either hacked into Tyco's computer systems or were given a copy of the report, which they used to rappel into the warehouse at the precise spot that allowed them to evade security cameras and motion detectors. They were then able to disable alarm systems and drive away with about $70 million worth of drugs. More from FiercePharmaManufacturing

@FiercePharma: Humor or fear? Merck uses both to promote shingles shot Zostavax. FiercePharmaMarketing story | Follow @FiercePharma

@CarlyHFierce: Switching study gives Celltrion biosim more ammo in fight for Remicade share. More from FiercePharmaMarketing | Follow @CarlyHFierce

> Bristol-Myers Squibb's ($BMY) PD-1 patent fight with Merck & Co. ($MRK) lives on, with a Delaware judge denying Merck's motion to dismiss the case. Report

> Indian regulators, in the wake of an unpopular ban on 344 combination drugs, are looking at another 619 combo products for potential action. Report

> Oregon's legislature is the latest to pass a law allowing pharmacies to substitute biosimilar drugs for their branded reference products, without doctor notification, so long as the biosim is deemed interchangeable by the FDA. Report

> The FDA is worried about false readings from devices that measure patients' blood clotting risks when they're taking anticoagulants such as warfarin; the measurements help inform dosage tweaks. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Theranos gets the boot as host for Clinton campaign fundraiser. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Med tech consultant discusses China FDA, tries to clear up Chinese clinical trial confusion. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: Embark Veterinary launches DNA testing kit for dogs with research applications in mind. FierceAnimalHealth story | Follow @EmilyWFierce

> 23andMe broadens R&D footprint with new genetic service through Apple's ResearchKit. Story

> San Diego's Acutus grabs $75M to get 3-D, real-time surgical cardiac imaging past regulators. More

> Endeavour Vision closes $275M dedicated med tech, digital health fund. Article

Biotech News

@FierceBiotech: Duchenne docs--AKA Sarepta investigators, advisers and advocates--back controversial case for eteplirsen. Article | Follow @FierceBiotech

@JohnCFierce: J&J joins up with Genentech for a pair of atezo/Darzalex combo cancer studies. News | Follow @JohnCFierce

> Pfizer joins next-gen vaccines R&D consortium. Item

> J&J joins up with Genentech for a pair of atezo/Darzalex combo cancer studies. Article

> Fledging biotech Syntimmune gains $10M tranche from its Series A nest egg. Report

> Will Eli Lilly's 11th-hour regulatory gambit salvage or sink its Alzheimer's drug? Editor's corner

Drug Delivery News

> S. Korean diabetes patch monitors blood sugar and delivers metformin. More

> GSK partnering with Germany's Miltenyi Biotec on cell and gene therapy R&D. Report

> Halozyme initiates Phase III trial of its internal pancreatic cancer candidate. Story

> 'Backpacks' on white blood cells could deliver cancer drugs in a targeted fashion. Article

> Inovio acquires needle-free jet injector tech from Bioject for $5.5M. News

Pharma Manufacturing News

> WHO suspends manufacturing approval of Indian TB drug maker Svizera. Report

> Hitachi Chemical and PCT ink deal for licensing, manufacturing for cell therapy. News

> Boehringer Ingelheim wins first client for China biologics plan. Story

> China hunts for $88M in vaccines diverted to black market. Item

> Marksans the latest Indian drugmaker cited with noncompliance by European regulators. Article

Pharma Asia News

> India's Svizera Labs suspended as TB drugs supplier to WHO. News

> Diabetes in focus as Lechleiter's Asian tour reaches China. Article

> CANbridge in potential $134M licensing deal with AVEO Oncology drug. Story

> Cancer care triage in Asia shows treatment options gap. More

> China FDA on the hunt for illegally sold vaccines in Shandong. Report

And Finally... The couple who made a fortune on Sucampo Pharmaceuticals--and later snapped up a variety of historic properties in Washington, DC--is divorcing, triggering complicated negotiations over ownership of their real estate. Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.